{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:52Z","timestamp":1792800892605,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Adjuvant anti\u2013programmed cell death protein 1 (anti\u2013PD-1) treatment improves outcomes in high-risk resected melanoma but causes chronic immune-related adverse events (irAEs) in more than 40% of patients. Risk factors associated with chronic vs acute irAEs remain lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify factors and possible candidate inflammatory pathways associated with the development of chronic nonendocrine irAEs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study was conducted from January 1, 2015, to December 31, 2024, at 7 institutions in the US and Australia. Patients had stage III to IV melanoma treated with adjuvant anti\u2013PD-1 therapy and more than 12 months of follow-up after discontinuation of anti\u2013PD-1 treatment.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Potential risk factors (age, sex, time to irAE onset, corticosteroid exposure, time to corticosteroid initiation, peak corticosteroid dose, and anti\u2013PD-1 treatment status) for chronic irAEs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incidence, type, and risk factors for chronic (persisting \u22653 months after anti\u2013PD-1 therapy cessation) irAEs and cytokine levels at 12 months after immune checkpoint inhibitor initiation were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 303 patients (median age at anti\u2013PD-1 therapy initiation, 64 years [IQR, 55-72 years]; 184 men [61%]), 220 (73%) developed acute irAEs and 146 (48%) developed chronic irAEs. The most common chronic irAEs were hypothyroidism (45 of 146 [31%]), arthritis (25 of 146 [17%]), and dermatitis (17 of 146 [12%]). Chronic irAEs had later onset (median, 153.0 days [IQR, 67.0-294.0 days] vs 99.0 days [IQR, 32.2-228.8 days];\n P<\/jats:italic>\n \u2009=\u2009.006) and more frequent corticosteroid exposure (35% [34 of 96] vs 24% [48 of 204];\n P<\/jats:italic>\n \u2009=\u2009.03) compared with nonchronic irAEs. For exploratory risk factor analysis of 300 nonendocrine irAE events, corticosteroid treatment and onset time had a significant interaction; corticosteroid-treated patients with earlier-onset irAEs had higher odds of developing chronic irAEs (odds ratio, 3.00; 95% CI, 1.45-6.22), adjusted for age, sex, and anti\u2013PD-1 therapy continuation. Eight different cytokines had higher circulating plasma levels among patients with chronic irAEs after false discovery rate (FDR) adjustment (including VEGFA and CCL19), and 19 cytokines had significantly higher circulating plasma levels prior to FDR adjustment. No cytokine levels were higher among controls.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with melanoma treated with adjuvant anti\u2013PD-1 therapy, chronic irAEs were common, persistent, and associated with elevated circulating cytokines, suggesting possible candidate inflammatory pathways for future validation. Later irAE onset and corticosteroid-treated irAEs were associated with chronicity of irAEs. Given the long-term survival of these patients, monitoring and managing chronic irAEs is crucial.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.37199","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:19Z","timestamp":1790955019000},"page":"e2637199","source":"Crossref","is-referenced-by-count":1,"title":["Anti\u2013PD-1 Therapy and Long-Term Toxic Effects Among Patients With Melanoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Roma A.","family":"Kankaria","sequence":"first","affiliation":[{"name":"Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reilly","family":"Fankhauser","sequence":"additional","affiliation":[{"name":"Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Boutros","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Pinzon","sequence":"additional","affiliation":[{"name":"The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheau-Chiann","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian B.","family":"Agbisit","sequence":"additional","affiliation":[{"name":"Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Kalyan","sequence":"additional","affiliation":[{"name":"NYU Langone Health Perlmutter Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleigha","family":"Lawless","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[{"name":"NYU Langone Health Perlmutter Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthee","family":"Rapisuwon","sequence":"additional","affiliation":[{"name":"Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Balko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[{"name":"Westmead Hospital, Westmead, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"8","key":"zoi261002r1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"zoi261002r2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2014update 2017.","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi261002r3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1189\/jlb.5RI0116-013RR","article-title":"Combinatorial approach to cancer immunotherapy: strength in numbers.","volume":"100","author":"Vilgelm","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"1","key":"zoi261002r4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma.","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi261002r5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFNa2b or ipilimumab in resected high-risk melanoma.","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"zoi261002r6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy.","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"8","key":"zoi261002r7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma.","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi261002r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113354","article-title":"Long-term outcomes and persistent toxicities following BRAF\/MEK inhibitor therapy for advanced melanoma.","volume":"194","author":"Goodman","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"zoi261002r9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma.","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi261002r10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamadermatol.2025.0025","article-title":"Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors.","volume":"161","author":"Fletcher","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"4","key":"zoi261002r11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity.","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"zoi261002r12","doi-asserted-by":"publisher","first-page":"e967","DOI":"10.1093\/oncolo\/oyac220","article-title":"Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge.","volume":"27","author":"Park","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"zoi261002r13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12967-019-02132-x","article-title":"Early fatigue in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: an insight from clinical practice.","volume":"17","author":"Cortellini","year":"2019","journal-title":"J Transl Med"},{"issue":"7","key":"zoi261002r14","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1007\/s00415-023-11667-5","article-title":"Dysautonomia associated with immune checkpoint inhibitors.","volume":"270","author":"Tezuka","year":"2023","journal-title":"J Neurol"},{"issue":"36","key":"zoi261002r15","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi261002r16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13075-025-03546-3","article-title":"Higher levels of VEGF-A and TNFa in patients with immune checkpoint inhibitor\u2013induced inflammatory arthritis.","volume":"27","author":"Gray-Gaillard","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"zoi261002r17","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events.","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi261002r18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/1346-8138.17183","article-title":"Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti\u2013PD-1 antibodies.","volume":"51","author":"Oya","year":"2024","journal-title":"J Dermatol"},{"issue":"1","key":"zoi261002r19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.","volume":"10","author":"Henderson Berg","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"zoi261002r20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12886-024-03575-7","article-title":"Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.","volume":"24","author":"Brown","year":"2024","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"zoi261002r21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark Res"},{"issue":"1","key":"zoi261002r22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2024.11.014","article-title":"Targeting molecular pathways to control immune checkpoint inhibitor toxicities.","volume":"46","author":"Reschke","year":"2025","journal-title":"Trends Immunol"},{"issue":"4","key":"zoi261002r23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids.","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"zoi261002r24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008482","article-title":"Inhibition of IL-25\/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.","volume":"12","author":"Hu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"9","key":"zoi261002r25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s43018-024-00804-2","article-title":"Targeting IL-17A to combat immune-related adverse events.","volume":"5","author":"Sierra-Davidson","year":"2024","journal-title":"Nat Cancer"},{"issue":"6","key":"zoi261002r26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy.","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"zoi261002r27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review.","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"7756","key":"zoi261002r28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"1","key":"zoi261002r29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"3","key":"zoi261002r30","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41591-025-04158-9","article-title":"Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.","volume":"32","author":"Hoeijmakers","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"zoi261002r31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41467-019-08352-5","article-title":"PD-1\/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.","volume":"10","author":"Rosenzweig","year":"2019","journal-title":"Nat Commun"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854762\/kankaria_2026_oi_261002_1790346348.33223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:30:20Z","timestamp":1790955020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.37199","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}